Lymphoma Clinical Trials in San Antonio

Showing 361-379 of 379 trials

S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00080847

This randomized phase II trial is studying rituximab and combination chemotherapy to see how well they work compared to oblimersen, rituximab, and combination chemotherapy in treating patients with advanced diffuse large B-cell non-Hodgkin's lymphoma. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of anticancer drugs by making cancer cells more sensitive to the drugs. Combining rituximab and combination chemotherapy with oblimersen may kill more cancer cells

Contiguous Stage II Adult Diffuse Large Cell LymphomaNoncontiguous Stage II Adult Diffuse Large Cell LymphomaStage III Adult Diffuse Large Cell Lymphoma+1 more

National Cancer Institute (NCI)160 participantsStarted Mar 2004

San Antonio, Texas, United States

TERMINATEDPhase 2< 1 mile

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma

NCT00843050

The purpose of this study is to determine whether P276-00 is safe and effective in treatment of Mantle Cell Lymphoma that is recurred after or not responding to at least one previous line of treatment.

Mantle Cell Lymphoma

Piramal Enterprises Limited13 participantsStarted Nov 2009

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Rochester, Minnesota, United States +17 more locations

S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma

Lymphoma Trials in Other Cities

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

Other Conditions in San Antonio